Twist Bioscience (TWST) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $6.9B
- As of Nov 13, 2026
- P/E
- -50.35x
- Trailing twelve months
- P/B
- 15.47x
- Latest reported equity
- P/S
- 15.97x
- Trailing twelve months
- ROE
- -30.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $6.9B
- As of Nov 13, 2026
- P/E
- -50.35x
- Trailing twelve months
- P/B
- 15.47x
- Latest reported equity
- P/S
- 15.97x
- Trailing twelve months
- ROE
- -30.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-50.35x
Net loss — not comparable
P/B
15.47x
P/S
15.97x
Earnings and dividend metrics▾
Earnings
EPS
-$2.17
Earnings per share
BPS
$7.08
Book value per share
ROE
-30.7%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $2.17 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $7.08 of net assets.
- ROE — shareholder equity shrank by 30.7% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q4)
Revenue increased 27.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Based on the company earnings press release. These figures come before the periodic report and may include adjusted measures.
Revenue · same quarter, three years
Year-ago quarter $99M+27.9%
From the company press release attached to an 8-K earnings filing. These figures come before the periodic report (10-Q or 10-K) and may include adjusted (non-GAAP) measures.
$86M
Jul–Sep '24
$99M
Jul–Sep '25
$126.6M
Jul–Sep '26
U.S. Eastern date
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 come from the company press release attached to an 8-K earnings filing submitted to SEC EDGAR on Nov 12, 2026.
- Press release figures come before the periodic report (10-Q or 10-K) and may include adjusted (non-GAAP) measures, so they can differ from later filings.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 27.9% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- The next earnings report is scheduled for Nov 16, 2026 (U.S. Eastern).
Filed Nov 12, 2026 · 8-K · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Korean AI analysis available →Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Leproust Emily M.Chief Executive Officer · Nov 3, 2026Open-market sale4,573 shares · $619KAvg. price $135.402558,187 shares held after
- Finn Patrick JohnPresident and COO · Nov 3, 2026Open-market sale2,565 shares · $347KAvg. price $135.402180,278 shares held after
- Green PaulaSVP of Human Resources · Nov 3, 2026Open-market sale1,007 shares · $136KAvg. price $135.402105,625 shares held after
- Cho DennisSee Remarks · Nov 3, 2026Open-market sale949 shares · $128KAvg. price $135.40262,840 shares held after
- WERNER ROBERT F.Chief Accounting Officer · Nov 3, 2026Open-market sale148 shares · $20KAvg. price $135.40242,769 shares held after
- Finn Patrick JohnPresident and COO · Oct 23, 2026Open-market sale2,245 shares · $302KAvg. price $134.589182,843 shares held after
- Laponis AdamChief Financial Officer · Oct 9, 2026Open-market sale2,462 shares · $385KAvg. price $156.304998,114 shares held after
- Leproust Emily M.Chief Executive Officer · Oct 5, 2026Open-market sale4,548 shares · $919KAvg. price $202.149
Show 8 price lots
- 1,840 shares × $200.4379$369K
- 1,017 shares × $202.3236$206K
- 481 shares × $201.2556$97K
- 432 shares × $203.6072$88K
- 297 shares × $205.7772$61K
- 290 shares × $204.7996$59K
- 146 shares × $206.8449$30K
- 45 shares × $207.4556$9K
- Leproust Emily M.Chief Executive Officer · Oct 2, 2026Open-market sale45,736 shares · $8.6MAvg. price $188.884567,308 shares held after
- Finn Patrick JohnPresident and COO · Oct 2, 2026Open-market sale25,714 shares · $4.9MAvg. price $188.884185,088 shares held after
- Green PaulaSVP of Human Resources · Oct 2, 2026Open-market sale10,088 shares · $1.9MAvg. price $188.884106,632 shares held after
- Cho DennisSee Remarks · Oct 2, 2026Open-market sale9,514 shares · $1.8MAvg. price $188.88463,789 shares held after
- Laponis AdamChief Financial Officer · Oct 2, 2026Open-market sale8,057 shares · $1.5MAvg. price $188.884100,576 shares held after
- WERNER ROBERT F.Chief Accounting Officer · Oct 2, 2026Open-market sale1,482 shares · $280KAvg. price $188.88442,917 shares held after
- Leproust Emily M.Chief Executive Officer · Oct 1, 2026Open-market sale655 shares · $131KAvg. price $200613,044 shares held after
- Leproust Emily M.Chief Executive Officer · Sep 24, 2026Open-market sale5,203 shares · $923KAvg. price $177.3797
Show 10 price lots
- 2,485 shares × $175.2313$435K
- 945 shares × $176.3917$167K
- 515 shares × $180.3911$93K
- 501 shares × $183.7641$92K
- 330 shares × $178.6683$59K
- 164 shares × $177.1699$29K
- 143 shares × $179.9331$26K
- 83 shares × $184.603$15K
- 21 shares × $181.4519$4K
- 16 shares × $182.5$3K
- Leproust Emily M.Chief Executive Officer · Sep 21, 2026Open-market sale1,687 shares · $279KAvg. price $165.491618,902 shares held after
- Cho DennisSee Remarks · Sep 21, 2026Open-market sale348 shares · $58KAvg. price $165.49173,303 shares held after
- Green PaulaSVP of Human Resources · Sep 21, 2026Open-market sale294 shares · $49KAvg. price $165.491116,720 shares held after
- Leproust Emily M.Chief Executive Officer · Sep 17, 2026Open-market sale316,188 shares · $50.0MAvg. price $158.1318
Show 5 price lots
- 232,173 shares × $158.0876$36.7M
- 32,260 shares × $157.486$5.1M
- 23,884 shares × $159.5315$3.8M
- 14,493 shares × $160.4392$2.3M
- 13,378 shares × $155.4568$2.1M
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Twist Bioscience (TWST) stock information
NASDAQ
Twist Bioscience (TWST) is listed on NASDAQ. Its market capitalization is about $6.9B. On trailing-twelve-month earnings the P/E ratio is -50.35, and the P/B ratio is 15.47. Return on equity is -30.7%. These figures are computed in-house from official filings and are reference information only.
Twist Bioscience — frequently asked questions
- What is the P/E ratio of Twist Bioscience (TWST)?
- On a trailing-twelve-month basis, TWST trades at a P/E ratio of -50.35. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Twist Bioscience?
- TWST has a market capitalization of about $6.9B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.